Assessment of Clinical, Biological and Biometrological Paramaters in Adult Subjects Suffering From AD
NCT ID: NCT05639738
Last Updated: 2022-12-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
12 participants
INTERVENTIONAL
2022-03-08
2022-06-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Collection of Clinical and Instrumental Data in Adult Subjects Suffering From Atopic Dermatitis
NCT04553224
Description of the Population With Moderate to Severe Atopic Dermatitis, Treated by Systemic Treatments and Needs Regarding Emollients
NCT06983561
Assessment of Clinical, Biological and Biometrological Parameters in Adults Subjects With Atopic Dermatitis
NCT07017348
Observational Evaluation of Atopic Dermatitis in Pediatric Patients
NCT03687359
A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.
NCT05689151
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
All subject
Clinical and instrumental measurements
Clinical and instrumental measurements
* Clinical evaluations
* Non-invasive instrumental measurements
* Subject's evaluations
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clinical and instrumental measurements
* Clinical evaluations
* Non-invasive instrumental measurements
* Subject's evaluations
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject suffering from Atopic Dermatitis according to the "U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis" (6)
* Subject with mild to moderate Atopic Dermatitis with 20 \<= SCORAD \<= 40 at inclusion
* Subject with flare frequency ≥ 4 on the target areas over the last year
* Subject with a cutaneous target area, allowing the measurements, located on upper or lower limbs and defined as a usual AD flare area according to the subject
* Subject with a target area with 22 \<= target SCORAD signs \<= 10 following:
* Erythema ≥ 1
* Dryness ≥ 1 1
* Subject with a control area, allowing the measurements, located on upper or lower limbs and defined as :
* A non- usual AD flare area according to the subject and the investigator
* A sufficient distance from the cutaneous target area according to the investigator
Exclusion Criteria
* Subject having any other dermatologic condition other than AD or characteristics (e.g: tatoo) on the target area liable to interfere with the study assessments
* Subject with another dermatologic condition, acute or chronic or disease or history of disease considered by the investigator, liable to interfere with the study assessments, or hazardous for the subject or incompatible with the study according to the investigator
* Any surgical intervention on upper or lower limbs during the previous weeks or months liable to interfere with the study data according to the investigator
* Systemic immunosuppressive therapy (excepted systemic corticoids) within 3 months before the inclusion visit or ongoing at inclusion visit (except during flare period)
* Systemic corticoids taken within 4 weeks before the inclusion visit or ongoing at inclusion visit (except during flare period)
* Phototherapy performed within 4 weeks before the inclusion visit or ongoing at inclusion visit (except during flare period)
* Systemic antibiotics taken within 7 days before the inclusion visit or ongoing at inclusion visit (except during flare period)
* Moderate to high-potency topical corticosteroids applied within 7 days on upper or lower limbs before the inclusion visit or ongoing at inclusion visit (except during flare period)
* Topical immunomodulators, applied within 7 days on upper or lower limbs before the inclusion visit or ongoing at inclusion visit (except during flare period)
* Topical or oral treatment instaurated or modified before the inclusion visit or planned to be instaurated during the study or ongoing at inclusion visit, liable to interfere with the study, according to the investigator
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pierre Fabre Dermo Cosmetique
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre de Recherche sur la Peau
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ADFLAREPREDICT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.